{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:38:49Z","timestamp":1775749129018,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Hope Run Special Fund of Cancer Foundation of China","award":["LC2022A10"],"award-info":[{"award-number":["LC2022A10"]}]},{"name":"Spark Plan","award":["XH-B051"],"award-info":[{"award-number":["XH-B051"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10637-024-01443-1","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T10:44:21Z","timestamp":1720694661000},"page":"454-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase I study of trifluridine\/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gongli","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongkun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"3","key":"1443_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1443_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM et al (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69(5):363\u2013385","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1443_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.21037\/atm-22-359","volume":"10","author":"S Lin","year":"2022","unstructured":"Lin S, Chen W, Chen Z, Liang J, Zhong L, Jiang M (2022) Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report. Ann Transl Med 10(6):380","journal-title":"Ann Transl Med"},{"issue":"23","key":"1443_CR4","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA et al (2017) Effect of First-Line Chemotherapy Combined with Cetuximab or Bevacizumab on overall survival in patients with KRAS Wild-Type Advanced or metastatic colorectal Cancer: a Randomized Clinical Trial. JAMA 317(23):2392\u20132401","journal-title":"JAMA"},{"issue":"20","key":"1443_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909\u20131919","journal-title":"N Engl J Med"},{"issue":"6","key":"1443_CR6","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3892\/or.2014.3487","volume":"32","author":"N Tanaka","year":"2014","unstructured":"Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F et al (2014) Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 32(6):2319\u20132326","journal-title":"Oncol Rep"},{"issue":"3","key":"1443_CR7","first-page":"1437","volume":"35","author":"M Nukatsuka","year":"2015","unstructured":"Nukatsuka M, Nakagawa F, Saito H, Sakata M, Uchida J, Takechi T (2015) Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res 35(3):1437\u20131445","journal-title":"Anticancer Res"},{"issue":"5","key":"1443_CR8","first-page":"2135","volume":"33","author":"H Tsukihara","year":"2015","unstructured":"Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H et al (2015) Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep 33(5):2135\u20132142","journal-title":"Oncol Rep"},{"issue":"1","key":"1443_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejca.2006.08.022","volume":"43","author":"OH Temmink","year":"2007","unstructured":"Temmink OH, Hoebe EK, Fukushima M, Peters GJ (2007) Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur J Cancer 43(1):175\u2013183","journal-title":"Eur J Cancer"},{"issue":"4","key":"1443_CR10","first-page":"545","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13(4):545\u2013549","journal-title":"Int J Mol Med"},{"issue":"3","key":"1443_CR11","first-page":"571","volume":"25","author":"T Emura","year":"2004","unstructured":"Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M (2004) A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 25(3):571\u2013578","journal-title":"Int J Oncol"},{"issue":"12","key":"1443_CR12","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-15-2783","volume":"22","author":"DL van der Velden","year":"2016","unstructured":"van der Velden DL, Opdam FL, Voest EE (2016) TAS-102 for treatment of Advanced Colorectal cancers that are no longer responding to other therapies. Clin Cancer Res 22(12):2835\u20132839","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1443_CR13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E et al (2023) Trifluridine-tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med 388(18):1657\u20131667","journal-title":"N Engl J Med"},{"issue":"7","key":"1443_CR14","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-19-2743","volume":"26","author":"AM Varghese","year":"2020","unstructured":"Varghese AM, Cardin DB, Hersch J, Benson AB, Hochster HS, Makris L et al (2020) Phase I study of Trifluridine\/Tipiracil plus irinotecan and Bevacizumab in Advanced gastrointestinal tumors. Clin Cancer Res 26(7):1555\u20131562","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1443_CR15","doi-asserted-by":"publisher","first-page":"e1108","DOI":"10.1093\/oncolo\/oyad143","volume":"28","author":"H Taniguchi","year":"2023","unstructured":"Taniguchi H, Yamazaki K, Masuishi T, Kawakami T, Onozawa Y, Honda K et al (2023) Bevacizumab, Irinotecan, and Biweekly Trifluridine\/Tipiracil for metastatic colorectal Cancer: MODURATE, a phase ib study. Oncologist 28(11):e1108\u2013e13","journal-title":"Oncologist"},{"issue":"5","key":"1443_CR16","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1007\/s10637-015-0271-1","volume":"33","author":"T Doi","year":"2015","unstructured":"Doi T, Yoshino T, Fuse N, Boku N, Yamazaki K, Koizumi W et al (2015) Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Invest New Drugs 33(5):1068\u20131077","journal-title":"Invest New Drugs"},{"issue":"12","key":"1443_CR17","doi-asserted-by":"publisher","first-page":"e1855","DOI":"10.1634\/theoncologist.2020-0643","volume":"25","author":"H Satake","year":"2020","unstructured":"Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H et al (2020) Phase Ib\/II study of Biweekly TAS-102 in combination with Bevacizumab for patients with metastatic colorectal Cancer refractory to standard therapies (BiTS study). Oncologist 25(12):e1855\u2013e63","journal-title":"Oncologist"},{"issue":"10","key":"1443_CR18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H et al (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13(10):993\u20131001","journal-title":"Lancet Oncol"},{"issue":"9","key":"1443_CR19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol 11(9):853\u2013860","journal-title":"Lancet Oncol"},{"issue":"5","key":"1443_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499\u2013508","journal-title":"Lancet Oncol"},{"issue":"28","key":"1443_CR21","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausov\u00e1 J, Macarulla T et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30(28):3499\u20133506","journal-title":"J Clin Oncol"},{"issue":"3","key":"1443_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/bjc.2012.274","volume":"107","author":"T Doi","year":"2012","unstructured":"Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A et al (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 107(3):429\u2013434","journal-title":"Br J Cancer"},{"issue":"10","key":"1443_CR23","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41416-023-02212-2","volume":"128","author":"Y Kuboki","year":"2023","unstructured":"Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H et al (2023) Trifluridine\/tipiracil\u2009+\u2009bevacizumab (BEV) vs. fluoropyrimidine-irinotecan\u2009+\u2009BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. Br J Cancer 128(10):1897\u20131905","journal-title":"Br J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01443-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01443-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01443-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T10:06:37Z","timestamp":1723716397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01443-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01443-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}